Consumer Health Cancer / Oncology
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabili...
September 23, 2025 | News
Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more th...
September 17, 2025 | News
Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on...
September 17, 2025 | News
Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...
September 16, 2025 | News
Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biolo...
September 16, 2025 | News
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...
September 12, 2025 | News
YouGov survey finds strong belief in value of early detection (78%) but low screening uptake (26%) 80% of respondents aware post-treatment care exists...
September 10, 2025 | Report
XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...
September 10, 2025 | News
FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line s...
September 08, 2025 | News
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has gran...
September 08, 2025 | News
Shanghai Henlius Biotech, Inc. and Organon announced that the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) inject...
September 04, 2025 | News
Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...
September 03, 2025 | News
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening Lunit , a leading provider o...
September 03, 2025 | News
Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...
September 01, 2025 | Company results
Most Read
Bio Jobs
News